These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12865732)

  • 1. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment.
    Brennan ML; Hazen SL
    Curr Opin Lipidol; 2003 Aug; 14(4):353-9. PubMed ID: 12865732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.
    Teng N; Maghzal GJ; Talib J; Rashid I; Lau AK; Stocker R
    Redox Rep; 2017 Mar; 22(2):51-73. PubMed ID: 27884085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloperoxidase and cardiovascular disease.
    Nicholls SJ; Hazen SL
    Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1102-11. PubMed ID: 15790935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of leukocyte-generated oxidants in left ventricular remodeling.
    Penn MS
    Am J Cardiol; 2008 May; 101(10A):30D-33D. PubMed ID: 18474271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease.
    Ndrepepa G
    Clin Chim Acta; 2019 Jun; 493():36-51. PubMed ID: 30797769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloperoxidase and coronary arterial disease: from research to clinical practice.
    Roman RM; Wendland AE; Polanczyk CA
    Arq Bras Cardiol; 2008 Jul; 91(1):e11-9. PubMed ID: 18660935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease.
    Anatoliotakis N; Deftereos S; Bouras G; Giannopoulos G; Tsounis D; Angelidis C; Kaoukis A; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):115-38. PubMed ID: 23470074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation.
    Zhang R; Brennan ML; Shen Z; MacPherson JC; Schmitt D; Molenda CE; Hazen SL
    J Biol Chem; 2002 Nov; 277(48):46116-22. PubMed ID: 12359714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease.
    Mayyas F; Baydoun D; Ibdah R; Ibrahim K
    J Cardiovasc Pharmacol Ther; 2018 May; 23(3):216-225. PubMed ID: 29343081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloperoxidase-generated oxidants and atherosclerosis.
    Podrez EA; Abu-Soud HM; Hazen SL
    Free Radic Biol Med; 2000 Jun; 28(12):1717-25. PubMed ID: 10946213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease.
    Nussbaum C; Klinke A; Adam M; Baldus S; Sperandio M
    Antioxid Redox Signal; 2013 Feb; 18(6):692-713. PubMed ID: 22823200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of myeloperoxidase in cardiology.
    Ikitimur B; Karadag B
    Future Cardiol; 2010 Sep; 6(5):693-702. PubMed ID: 20932115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A myeloperoxidase precursor, pro-myeloperoxidase, is present in human plasma and elevated in cardiovascular disease patients.
    Khalilova IS; Dickerhof N; Mocatta TJ; Bhagra CJ; McClean DR; Obinger C; Kettle AJ
    PLoS One; 2018; 13(3):e0192952. PubMed ID: 29590135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection.
    Ramachandra CJA; Ja KPMM; Chua J; Cong S; Shim W; Hausenloy DJ
    Antioxid Redox Signal; 2020 May; 32(15):1135-1149. PubMed ID: 31847538
    [No Abstract]   [Full Text] [Related]  

  • 15. The other myeloperoxidase: Emerging functions.
    Vanhamme L; Zouaoui Boudjeltia K; Van Antwerpen P; Delporte C
    Arch Biochem Biophys; 2018 Jul; 649():1-14. PubMed ID: 29614255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?
    Schindhelm RK; van der Zwan LP; Teerlink T; Scheffer PG
    Clin Chem; 2009 Aug; 55(8):1462-70. PubMed ID: 19556446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative damage markers and antioxidants in patients with acute myocardial infarction and their clinical significance.
    Ho HY; Cheng ML; Chen CM; Gu PW; Wang YL; Li JM; Chiu DT
    Biofactors; 2008; 34(2):135-45. PubMed ID: 19706979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events.
    Wong ND; Gransar H; Narula J; Shaw L; Moon JH; Miranda-Peats R; Rozanski A; Hayes SW; Thomson LE; Friedman JD; Berman DS
    JACC Cardiovasc Imaging; 2009 Sep; 2(9):1093-9. PubMed ID: 19761988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.